Work

Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Year: 2015

Type: article

Source: Blood

DOI: 10.1182/blood.v126.23.2730.2730

Authors: John M. Rossi, Sattva S. Neelapu, William Y. Go, Yueh-wei Shen, Marika Sherman, Frederick L. Locke, Nancy L Bartlett, Tanya Siddiqi, Lynn Navale, Meg Elias, Jeff Wiezorek, Adrian Bot

Institutions: Kite Pharma (United States), The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Washington University in St. Louis, City Of Hope National Medical Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4247240455

FWCI:

Cites:

Cited by: 1

Related to: 10